Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

Inclusion Criteria: * Healthy male or female adult subjects aged ≥ 18 to ≤ 55 years * Females must be either postmenopausal or sterile * Body weight between ≥ 50 and ≤ 110 kg and body mass index between ≥ 18.0 kg/m2 and ≤ 30 kg/m2 Exclusion Criteria: * History or current evidence of a clinically significant medical condition, disorder, or disease, including but not limited to any of the following: hepatic (hepatitis, cirrhosis, or history of liver disease, drug reaction, or aminotransaminase elevations, if known); biliary; renal; cardiac; bronchopulmonary; vascular; hematologic; gastrointestinal; allergy; endocrine / metabolic (diabetes, thyroid disorders, adrenal disease); neurologic (including history of migraine); psychiatric; immunologic; dermatologic; oncologic (subjects with resected cervical or skin cancer \[except melanoma\] who have had no evidence of disease in the last 5 years are eligible), that precludes designation of healthy subjects as judged by the Investigator * History or evidence of congenital or acquired immunosuppressive condition(s), including positive serology for human immunodeficiency virus infection or taking immunosuppressive agents. * Evidence of active or latent tuberculosis * Hospitalization within 3 months before IP administration or planned hospitalization at any time during the study. * History of any drug allergy, hypersensitivity (excluding hay fever) or intolerance to latex or any drug product * A positive test result for drugs of abuse. * Smokers within 3 months before Screening.